Pediatric research
This article was originally published in The Tan Sheet
Executive Summary
User fee exemption for pediatric drug supplements repealed under "Best Pharmaceuticals for Children Act," signed by President Bush Jan. 4. Under the law, which reauthorizes pediatric exclusivity provisions, all pediatric supplements that require clinical data for approvals, even if the supplement is for a new indication, must pay fees unless otherwise eligible for waivers. Law also directs FDA not to delay ANDA approvals based on pediatric labeling disputes (1"The Tan Sheet" Nov. 26, 2001, p. 21)...
You may also be interested in...
FDA Pediatric Therapeutics Office To Consider Ethics, Postmarket Safety
FDA is in the process of hiring an epidemiologist to coordinate epidemiology and safety reviews of approved pediatric products within the newly created Office of Pediatric Therapeutics
ANDA Bioequivalence Data Subject Of Upcoming FDA Proposed Rule
FDA expects to issue an advance notice of proposed rulemaking in November requiring ANDA applicants to include data from all bioequivalence studies conducted on a drug formulation with their application
Pediatric Rule “Parts” To Be Cut In Light Of Exclusivity Provisions – Crawford
FDA will decide which sections of its 1998 pediatric rule to keep and which to eliminate "over the next several weeks," FDA Acting Commissioner Lester Crawford, PhD, told the Senate Appropriations/ Agriculture Subcommittee March 20